FDA
-
-
-
-
-
-
-
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
-
-
-
-
-
-
-
Salarius reports studies support seclidemstat's LSD1 inhibition role
-
-
-
-
-
-
-
Salarius Pharmaceuticals (SLRX) Issues Update on Strategic Review Process, Will Support Ongoing Seclidemstat Clinical Trials by Further Cost Cuts
-
-
-
-
-
-
-
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
-
-
-
-
-
-
-
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
-
-
-
-
-
-
-
Salarius Pharmaceuticals (SLRX) Reports No Adverse Safety Signals from Two Toxicology Studies of SP-3164
-
-
-
-
-
-
-
Salarius Pharmaceuticals, Inc. (SLRX) Receives $1.48M from the Cancer Prevention and Research Institute of Texas
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

